Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Sinovac’s Pioneering EV71 Vaccine Set To Reach First Market

This article was originally published in PharmAsia News

Executive Summary

The China FDA has given a production nod to Beijing Sinovac for its EV71 vaccine, which now appears set to be the first product of its type globally to be commercialized. The company expects to launch the vaccine in June and is also actively seeking partners in other Asian countries.

You may also be interested in...



Sinovac Take-Private Deal Facing Challenges

Sinovac’s lengthy take-private process could be further delayed by the cloudy outlook for a potential relisting in China due to regulatory uncertainty and a tougher domestic environment, although the Chinese company’s rising competitiveness in the domestic vaccines market should help increase its valuation.

Key Role For China As Sanofi’s Emerging Markets Business Grows

Continuing with a double-digit growth rate, China remained a leading driver for Sanofi’s global business in the fourth quarter. Going digital and building local partnerships emerged as key themes for Sanofi China to explore more opportunities, although it may face testing problems for its vaccine business in the country.

Deal Watch: Avid Transitions Into CDMO By Offloading Cancer Program To Oncologie

Oncologie acquires PS-targeting candidate bavituximab, which may help other cancer therapies in attacking tumors. BridgeBio's newest spinout will develop former Novartis cancer candidate infigratinib.

Topics

Related Companies

UsernamePublicRestriction

Register

LL1132999

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel